Coordination Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2017-01-01
- Employees
- 1
- Market Cap
- -
Phase I Study of RiMO-401 With Radiation in Advanced Tumors
Phase 1
Recruiting
- Conditions
- Advanced Solid TumorIntratumoral Injection
- Interventions
- Drug: RiMO-401
- First Posted Date
- 2023-12-27
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Coordination Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT06182579
- Locations
- 🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States
Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer
Phase 1
Recruiting
- Conditions
- Head Neck CancerIntratumoral Injection
- Interventions
- Drug: RiMO-301
- First Posted Date
- 2023-05-01
- Last Posted Date
- 2023-12-18
- Lead Sponsor
- Coordination Pharmaceuticals, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT05838729
- Locations
- 🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States
Phase I Study of CPI-300 in Patients With Advanced Tumors
Phase 1
Completed
- Conditions
- Advanced Tumors
- Interventions
- Drug: CPI-300
- First Posted Date
- 2021-03-22
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Coordination Pharmaceuticals, Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT04808453
- Locations
- 🇺🇸
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
🇺🇸Honor Health Research Institute, Scottsdale, Arizona, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
Study of CPI-200 in Patients With Advanced Tumors
Phase 1
Completed
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: CPI-200
- First Posted Date
- 2019-05-17
- Last Posted Date
- 2022-02-24
- Lead Sponsor
- Coordination Pharmaceuticals, Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT03953742
- Locations
- 🇺🇸
South Texas Accelerated Research Therapeutics (START Midwest), Grand Rapids, Michigan, United States
Study of CPI-100 in Patients With Advanced Tumors
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2022-07-20
- Lead Sponsor
- Coordination Pharmaceuticals, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT03781362
- Locations
- 🇺🇸
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
🇺🇸South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States
Phase I Study of RiMO-301 With Radiation in Advanced Tumors
Phase 1
Recruiting
- Conditions
- Advanced Tumors
- Interventions
- Drug: RiMO-301
- First Posted Date
- 2018-02-23
- Last Posted Date
- 2024-02-15
- Lead Sponsor
- Coordination Pharmaceuticals, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT03444714
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸University of Illinois at Chicago, Chicago, Illinois, United States
© Copyright 2025. All Rights Reserved by MedPath